Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Florida Cancer Specialists S.
mi
from
Fort Myers, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Florida Cancer Specialists S.
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Baptist Health Medical Group Oncology, LLC
mi
from
Miami, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Baptist Health Medical Group Oncology, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Community Clinical Research Center
mi
from
Anderson, IN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Community Clinical Research Center
mi
from
Anderson, IN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Ft. Wayne Med Onco-Hema Inc
mi
from
Fort Wayne, IN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Ft. Wayne Med Onco-Hema Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Christus St. Francis Cabrini Cancer Center
mi
from
Alexandria, LA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Christus St. Francis Cabrini Cancer Center
mi
from
Alexandria, LA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
W.G. (Bill) Hefner VA Medical Center
mi
from
Salisbury, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
W.G. (Bill) Hefner VA Medical Center
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Louis Stokes Cleveland VA Medical Center
mi
from
Cleveland, OH
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Louis Stokes Cleveland VA Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Arizona Oncology Assoc, Pc-Hal
mi
from
Phoenix, AZ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Arizona Oncology Assoc, Pc-Hal
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
University of Florida - Shands
mi
from
Gainesville, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
University of Florida - Shands
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cancer Treatment Centers of America
mi
from
Newnan, GA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cancer Treatment Centers of America
mi
from
Newnan, GA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Moses Cone Health System
mi
from
Greensboro, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Moses Cone Health System
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Sanford Research
mi
from
Sioux Falls, SD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Sanford Research
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Scripps Cancer Center
mi
from
La Jolla, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Scripps Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Memorial Cancer Institute
mi
from
Hollywood, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
New England Cancer Specialists
mi
from
Scarborough, ME
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
New England Cancer Specialists
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Hunterdon Medical Center
mi
from
Flemington, NJ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Hunterdon Medical Center
mi
from
Flemington, NJ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Atlantic Health System
mi
from
Summit, NJ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Atlantic Health System
mi
from
Summit, NJ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Morristown Medical Center
mi
from
Summit, NJ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Morristown Medical Center
mi
from
Summit, NJ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Randolph Cancer Center
mi
from
Greensboro, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Randolph Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cancer Care Center
mi
from
Bismarck, ND
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cancer Care Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Mid Ohio Oncology Hematology, Inc.
mi
from
Columbus, OH
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Mid Ohio Oncology Hematology, Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
Houston, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cancer Centers of South Texas
mi
from
San Antonio, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cancer Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Summit Medical Group
mi
from
Morristown, NJ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Summit Medical Group
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Northern Westchester Hospital
mi
from
Mount Kisco, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Northern Westchester Hospital
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Investigational Products Ctr
mi
from
Irving, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Investigational Products Ctr
mi
from
Irving, TX
Click here to add this to my saved trials
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  5/1/2018
UCSF Breast Care Center
mi
from
San Francisco, CA
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 5/1/2018
UCSF Breast Care Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Miami, FL
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Tampa, FL
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Chicago, IL
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Louisville, KY
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Albuquerque, NM
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
New York, NY
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Portland, OR
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Memphis, TN
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Nashville, TN
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
Clinical Research Facility
mi
from
Houston, TX
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated:  5/1/2018
mi
from
Buenos Aires,
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status: Enrolling
Updated: 5/1/2018
mi
from
Buenos Aires,
Click here to add this to my saved trials
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Status: Enrolling
Updated:  5/1/2018
Department of Psychology
mi
from
Coral Gables, FL
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Status: Enrolling
Updated: 5/1/2018
Department of Psychology
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Lincoln Hospital and Mental Health Center
mi
from
Bronx, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Lincoln Hospital and Mental Health Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Click here to add this to my saved trials